Rigosertib
Drug timelines are a Plus or Pro feature.
16 regulatory and trial events tracked for Rigosertib, covering 2017-06-23 to 2026-04-27. Get the full timeline:
Most recent: Clinical Trial Update: Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors [Phase 2]